Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Eisai Restructures Global R&D, Cuts 130 Positions

By Drug Discovery Trends Editor | December 3, 2013

Eisai Co. Ltd. announced today that the company’s research and development organization, Eisai Product Creation Systems (EPCS), has undergone a transformation with the aim of further focusing and strengthening its product creation capabilities. In order to fulfill its sole mission of ensuring that innovative new drugs that meet unmet medical needs are made available to patients as early as possible, EPCS has flexibly implemented organizational changes deemed necessary according to the progress of Eisai’s development pipeline. The changes will allow Eisai to better prioritize and define its product creation activities by creating a leaner organizational structure that will more efficiently drive forward high-priority projects, increase focus on next-generation products and investigational compounds, and enhance the pursuit of innovation during development and discovery. 
 
To reflect Eisai’s increased focus on key drug discovery areas, EPCS has undergone a shift in its structure. Previously, EPCS had a centralized management model within a single Core Function Unit (CFU) for clinical support functions worldwide. The new model has transferred those management responsibilities to other PCUs/CFUs in order to streamline communications and decision making. Other key clinical support functions such as those for statistical analysis and clinical pharmacology have been placed under the direct jurisdiction of the CCLO in an effort to further improve clinical success rates. The former Scientific & Operational Clinical Support (SOCS) CFU has also been dissolved as part of these changes.
 
Additionally, in regard to drug discovery in the area of neuroscience at Eisai’s Europe, the Middle East, Africa and Oceania (EMEA) Knowledge Centre (EKC) in the United Kingdom, focus on the Open Innovation function, which primarily conducts joint research with University College London, has been increased, while the EKC’s medicinal chemistry function has been dissolved.
 
To support advancements in Eisai’s development pipeline, functions for small-molecule process development have been consolidated in Japan (Kashima, Tsukuba) and India (Vizag), while the related functions at the Andover site in the United States have been dissolved. Andover will continue to serve as the discovery research hub in the United States.
 
At the same time, in order to further strengthen and promote development of biopharmaceuticals as next-generation drugs, the biopharmaceutical development functions that had been divided between research sites in the United States (Exton, Andover) have been consolidated into the newly established Biopharmaceutical Development Department, which is located at the Exton site. 
 
The reorganizations will result in the reduction of approximately 130 positions in Europe and the United States.
 
 
Date: November 29, 2013
Source: Eisai Co. Ltd.

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE